Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to approval will be clear as soon as the vaccine maker and the regulator agree on the ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.

Senior leaders at the US Food and Drug Administration began pushing Moderna Inc. and Pfizer Inc. to file for full, formal ...

Officials in sixteen states and the District of Columbia sued in response, leading to Tuesday’s order from U.S. District ...

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.